PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, announced that shareholders approved all proposals put forward by the Board of Directors at the Company’s fifth annual General Meeting with a large majority. The meeting, held at the Chollerhalle in Zug, saw 80.85% of issued registered shares represented, totaling 26,780,855 shares with voting rights.
The re-election of all six Board members, including Peter Wilden as Chair and Philippe Weber and Peter Wilden to the Remuneration and Nomination Committee, underscores continuity in leadership as the company navigates a fast-growing peptide market, particularly in metabolic diseases like GLP-1. Shareholders also approved the re-election of Statutory Auditors and the Independent Proxy, as well as the maximum aggregate compensation for the Board and Executive Committee.
Discharge was granted to all Board and Executive Committee members for their activities in financial year 2025, and the Management Report, Statutory Financial Statements, Consolidated Financial Statements, and the non-financial matters report were approved. The Remuneration Report 2025 passed in a separate consultative vote. The next AGM is scheduled for April 7, 2027.
The strong shareholder support signals confidence in PolyPeptide's strategic direction as a specialized CDMO with six GMP-certified facilities globally. The company's focus on peptide-based APIs positions it to capitalize on growing demand for peptide therapeutics. Minutes of the AGM will be available within 15 days on the Company’s website.
